Cangene announces second quarter financial results for fiscal 2010

Readers are referred to the cautionary notes regarding Forward-looking Information and non-GAAP Financial Measures at the end of this release

Listed TSX, Symbol: CNJ

TORONTO and WINNIPEG, March 16 /CNW/ - Cangene Corporation today reports financial results for the second quarter ended January 31, 2010.

Revenues for the second quarter of 2010 were $41.5 million, 20% higher than the $34.5 million recorded during the same period last year. The higher revenue in the current quarter reflects deliveries on U.S. government stockpiling contracts that generated $18.3 million in product revenue in the quarter. Partially offsetting this was reduced R&D-services revenue from development activities related to these and other third-party contracts. In total, R&D-services revenues declined to $4.1 million in the current quarter from $11.0 million in the prior-year quarter. Overall, $22.3 million in revenue was recognized on these stockpiling contracts in the current quarter, compared with $7.3 million in the first quarter of 2009. While contract-services revenues have increased by $11.1 million year-over-year for the quarter, biopharmaceutical sales declined by $4.1 million. This decrease reflects the fact that the Company is no longer receiving R&D revenues in that segment as joint-development agreements with Apotex have been concluded. Additionally, sales of WinRho(R) SDF have decreased from the year-earlier quarter, although this decrease is partially offset by a $1.5 million increase in HepaGam B(R) sales as the Company is no longer sharing this revenue with Apotex. Gross margin for the quarter has decreased to 43% from 52% in the prior year, largely due to a combination of plasma centre start-up costs, higher overheads due to lower manufacturing activity, a shift in revenue mix, and, higher long-term incentive costs.

"Our financial results for the quarter reflect the opposing combination of increased deliveries on biodefence contracts and higher operating costs, including the costs of establishing our commercial operations in the U.S. at Cangene bioPharma, Inc., our Baltimore-based subsidiary," said Dr. John Langstaff, Cangene's president and CEO.

Net income for the quarter was $3.8 million or $0.06 per share, compared with $5.6 million or $0.08 per share in the same quarter last year. The drop in net income resulted largely from the lower gross margin in the quarter, along with increased SG&A and amortization expenses. The increased SG&A results from higher incentive plan compensation expense and costs associated with building the sales force at Cangene bioPharma.

An $8.8-million increase in net non-cash working capital balances and other assets related to operations in the quarter resulted from increased inventories and contracts in progress, increased accounts receivable, and increased income and other taxes recoverable, combined with decreased accounts payable and accrued liabilities. By comparison, the second quarter of 2009 included a significant decrease in accounts receivable offset by a significant increase in inventories and contracts in progress, in addition to increased income and other taxes recoverable, and lower accounts payable and accrued liabilities.

At January 31, 2010, the Company had $30.2 million in cash and no debt.

Readers are referred to the cautionary notes regarding Forward-looking Information and non-GAAP Financial Measures at the end of this release. Certain comparative figures in the following financial statements have been reclassified to conform to the current year's presentation.

Conference Call

Cangene will host a conference call to discuss these financial results on Wednesday, March 17, 2010 at 11:00 a.m. Eastern. To access the conference call by telephone, dial 647-427-7450 or 1-888-231-8191. The conference call will be archived for replay until Wednesday, March 24 2010, at midnight. To access the archived conference call, dial 416-849-0833 or 1-800-642-1687 and enter the reservation number 61832411 followed by the number sign.

A live audio webcast of the conference call will be available at www.cangene.com and www.newswire.ca. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived at the above web sites for 90 days.

    
    CANGENE CORPORATION
    CONSOLIDATED BALANCE SHEETS (unaudited)

                                      Incorporated under the laws of Ontario

                                                              At          At
                                                      January 31,    July 31,
    in thousands of Canadian dollars                        2010        2009
    -------------------------------------------------------------------------

    ASSETS
    Current
    Cash                                               $  30,213   $  56,131
    Accounts receivable                                   42,734      34,547
    Inventories and contracts in progress                 99,534      92,430
    Income and other taxes recoverable                    10,632       5,637
    Future income taxes                                    5,400       8,231
    Prepaid expenses and deposits                          2,979       2,830
    -------------------------------------------------------------------------
    Total current assets                                 191,492     199,806
    Property, plant and equipment, net                    95,934      96,405
    Future income taxes                                    2,403           -
    Goodwill and intangible assets                        57,689      43,520
    Other assets                                           4,327       5,460
    -------------------------------------------------------------------------
                                                       $ 351,845   $ 345,191
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------

    LIABILITIES AND SHAREHOLDERS' EQUITY
    Current
    Accounts payable and accrued liabilities           $  20,623   $  27,948
    Income and other taxes payable                            17       4,126
    Current portion of deferred income                     5,525       5,875
    -------------------------------------------------------------------------
    Total current liabilities                             26,165      37,949
    Deferred income                                       11,294       9,906
    Royalty liability                                      7,137           -
    Incentive plan liabilities                             4,735         122
    Deferred share units                                     141           -
    Future income taxes                                    3,229       5,522
    -------------------------------------------------------------------------
    Total liabilities                                     52,701      53,499
    -------------------------------------------------------------------------

    Shareholders' equity
    Share capital                                         65,356      65,655
    Contributed surplus                                    3,239       3,239
    Accumulated other comprehensive loss                  (4,467)     (4,467)
    Retained earnings                                    235,016     227,265
    -------------------------------------------------------------------------
    Total shareholders' equity                           299,144     291,692
    -------------------------------------------------------------------------
                                                       $ 351,845   $ 345,191
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------



    CANGENE CORPORATION
    CONSOLIDATED STATEMENTS OF INCOME, COMPREHENSIVE INCOME AND RETAINED
    EARNINGS (unaudited)

                                   Three       Three         Six         Six
    in thousands of               months      months      months      months
     Canadian dollars              ended       ended       ended       ended
     except share-related     January 31, January 31, January 31, January 31,
     data                           2010        2009        2010        2009
    -------------------------------------------------------------------------

    Revenues
    Product sales and services $  35,542   $  21,587   $  67,517   $  56,097
    R&D services                   4,123      11,036      11,946      26,588
    Royalties                      1,871       1,920       4,105       4,082
    -------------------------------------------------------------------------
                                  41,536      34,543      83,568      86,767
    -------------------------------------------------------------------------

    Cost of sales
    Product sales and services    20,421       9,020      36,133      22,015
    R&D services                   3,051       7,580       9,320      18,435
    -------------------------------------------------------------------------
                                  23,472      16,600      45,453      40,450
    -------------------------------------------------------------------------

    Gross profit                  18,064      17,943      38,115      46,317
    -------------------------------------------------------------------------

    Expenses
    Independent R&D                2,723       2,484       6,184       4,031
    Selling, general and
     administrative                7,413       5,614      12,466      10,829
    Amortization                   3,868       3,217       7,157       6,293
    Interest income
      Short-term                      (8)         (6)        (33)        (42)
    Foreign-exchange loss (gain)    (210)       (784)        733     (10,949)
    -------------------------------------------------------------------------
                                  13,786      10,525      26,507      10,162
    -------------------------------------------------------------------------
    Income before income taxes     4,278       7,418      11,608      36,155
    -------------------------------------------------------------------------
    Income tax expense (recovery)
      Current                      2,313         894       3,049       8,238
      Future                      (1,818)        936        (544)      1,194
    -------------------------------------------------------------------------
                                     495       1,830       2,505       9,432
    -------------------------------------------------------------------------
    Net income and comprehensive
     income for the period         3,783       5,588       9,103      26,723

    Retained earnings, beginning
     of period                   232,222     192,676     227,265     172,900
    Purchase of common shares
     in excess of average
     stated capital                 (989)       (621)     (1,352)     (1,980)
    -------------------------------------------------------------------------
    Retained earnings,
     end of period             $ 235,016   $ 197,643   $ 235,016   $ 197,643
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------

    Basic and diluted earnings
     per share                 $    0.06   $    0.08   $    0.13   $    0.38



    CANGENE CORPORATION
    CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)

                                   Three       Three         Six         Six
                                  months      months      months      months
                                   ended       ended       ended       ended
    in thousands of           January 31, January 31, January 31, January 31,
     Canadian dollars               2010        2009        2010        2009
    -------------------------------------------------------------------------

    OPERATING ACTIVITIES
    Net income for the period  $   3,783   $   5,588   $   9,103   $  26,723
    Add (deduct) items not
     involving cash:
      Amortization of property,
       plant & equipment           3,075       2,865       6,138       5,624
      Amortization of intangible
       assets                        793         352       1,019         669
      Deferred income                873      (1,257)      1,038      (1,350)
      Incentive plan liabilities   2,587         488       4,613         488
      Deferred share unit
       liability                      81           -         141           -
      Amortization of royalty
       liability                    (326)          -        (326)          -
      Future income tax expense
       (recovery)                 (1,818)        936        (544)      1,194
      Unrealized foreign-exchange
       loss (gain)                  (174)        587        (645)     (1,105)
    -------------------------------------------------------------------------
                                   8,874       9,559      20,537      32,243
    Net change in non-cash
     working capital balances
     and other assets related
     to operations                (8,775)    (12,392)    (30,736)    (30,319)
    -------------------------------------------------------------------------
    Cash provided by (used in)
     operating activities             99      (2,833)    (10,199)      1,924
    -------------------------------------------------------------------------

    INVESTING ACTIVITIES
    Purchase of property, plant
     and equipment, net           (3,719)     (2,313)     (5,667)     (5,510)
    Acquisition of intangible
     assets                          (23)        (84)     (7,719)       (428)
    -------------------------------------------------------------------------
    Cash used in investing
     activities                   (3,742)     (2,397)    (13,386)     (5,938)
    -------------------------------------------------------------------------

    FINANCING ACTIVITIES
    Shares repurchased for
     cancellation                 (1,252)       (769)     (1,713)     (2,495)
    -------------------------------------------------------------------------
    Cash used in financing
     activities                   (1,252)       (769)     (1,713)     (2,495)
    -------------------------------------------------------------------------
    Effect of exchange rates
     on cash                        (137)        336        (620)      2,173
    -------------------------------------------------------------------------

    Net decrease in cash during
     the period                   (5,032)     (5,663)    (25,918)     (4,336)
    Cash, beginning of period     35,245      16,002      56,131      14,675
    -------------------------------------------------------------------------
    Cash, end of period        $  30,213   $  10,339   $  30,213   $  10,339
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------

    Interest paid              $       1   $      11   $       1   $      46
    Income taxes paid          $   1,142   $   4,114   $   8,040   $   5,188
    

About Cangene Corporation

Cangene is one of Canada's largest and earliest biopharmaceutical companies. It was founded in 1984 and is headquartered in Winnipeg, Manitoba. Cangene has approximately 700 employees in eight locations across North America and its products are sold worldwide. It operates three large manufacturing facilities - two in Winnipeg, Manitoba and one in Baltimore, Maryland - where it produces its own products and undertakes contract manufacturing for a number of companies. Cangene operates three U.S. and one Canadian plasma-collection facilities branded as Cangene Plasma Resources. In addition, it has a regulatory affairs, sales and corporate communications office in Toronto, Ontario.

Cangene is focused on developing therapeutics for infectious diseases, and the Company uses patented manufacturing processes to produce plasma-derived and recombinant therapeutic proteins. Cangene has five FDA and/or Health Canada-approved products. In addition, the Company has several more products in development at various stages. Three of Cangene's products have been accepted into the U.S. Strategic National Stockpile-botulism antitoxin (investigational product), anthrax immune globulin (investigational product) and vaccinia immune globulin, a product used to counteract certain complications that may arise from smallpox vaccination.

Capitalizing on its drug manufacturing expertise, Cangene also operates a significant contract research and manufacturing business using the resources of Baltimore, Maryland-based Cangene bioPharma, Inc. (a wholly owned subsidiary; formerly Chesapeake Biological Laboratories, Inc.). Cangene's website, www.cangene.com, includes product and investor information, including past news releases. Further information about Cangene bioPharma can be found at www.cangenebiopharma.com and information about Cangene's plasma donation programs can be found at www.cangeneplasma.com.

Forward-looking and risk information

The reader should be aware that Cangene's businesses are subject to risks and uncertainties that cannot be predicted or quantified; consequently, actual results may differ materially from past results and those expressed or implied by any forward-looking statements. Factors that could cause or contribute to such risks or uncertainties include, but are not limited to: the regulatory environment including the difficulty of predicting regulatory outcomes; changes in the value of the Canadian dollar; the Company's reliance on a small number of customers including government organizations; the demand for new products and the impact of competitive products, service and pricing; availability and cost of raw materials, especially the cost, availability and antibody concentration in plasma; fluctuations in operating results; government policies or actions; progress and cost of clinical trials; reliance on key strategic relationships; costs and possible development delays resulting from use of legal, regulatory or legislative strategies by the Company's competitors; uncertainty related to intellectual property protection and potential costs associated with its defence; the Company's exposure to lawsuits; and other matters beyond control of management. Risks and uncertainties are discussed more extensively in the MD&A section of the Company's most recent annual report and annual information form, which are available on the Company's website or on SEDAR at www.sedar.com.

Cautionary Note Regarding Non-GAAP Financial Measures

This news release may contain non-GAAP financial measures. Terms by which non-GAAP financial measures are identified include but are not limited to "net cash", "total assets", "sales" and other similar expressions. Non-GAAP financial measures are used to provide management and investors with additional measures of performance. However, non-GAAP financial measures do not have standard meanings prescribed by GAAP and are not directly comparable to similar measures used by other companies. Please refer to the appropriate reconciliations of these non-GAAP financial measures to measures prescribed by GAAP.

The preceding cautionary statements should be considered in connection with all written or oral statements, especially forward-looking statements, that are made by the Company or by persons acting on its behalf and in conjunction with its periodic filings with Securities Commissions, including those contained in the Company's news releases and most recently filed annual information form. Forward-looking statements can be identified by the use of words such as "expects", "plans", "will", "believes", "estimates", "intends", "may", "bodes" and other words of similar meaning (including negative and grammatical variations). Should known or unknown risks or uncertainties materialize, or should management's assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly make or update any forward-looking statements, except as required by applicable law.

"Cangene", "HepaGam B", "WinRho" and "WinRho SDF" are trademarks belonging to Cangene Corporation.

%SEDAR: 00002351E

SOURCE Cangene Corporation

For further information: For further information: about Cangene Corporation, please contact Michael Graham at (204) 275-4040 or by email at mgraham@cangene.com

Organization Profile

Cangene Corporation

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890